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ABSTRACT
Objective: The purpose of this study was to assess the effect of several maternal variables on the
serologic response following the treatment of syphilis in pregnancy.
Methods: A 5-year chart review identified 95 patients coded with syphilis at Hermann Hospital.
Inclusion criteria were 1) serologically confirmed syphilis infection during the index pregnancy, 2)
complete treatment during the index pregnancy, and 3) minimum of one follow-up rapid plasma
reagin (RPR) titer. Forty-nine of 95 patients met the inclusion criteria. Treatment response was
evaluated by comparing each post-treatment titer of a patient to her pretreatment titer. Each
comparison was considered an "observation." Each observation was classified as either a positive
response (->4-fold titer decline) or a negative response (<4-fold titer decline). Maternal variables
assessed included 1) prior history of syphilis untreated or incompletely treated prior to the index
pregnancy, 2) gestational age, 3) titer level, 4) unknown duration, 5) positive response at 1 month,
6) positive response at 2 months, 7) positive response at >3 months, and 8) race.
Results: A positive response following treatment was significantly more likely if there was no
prior history of syphilis or if there was a high initial RPR titer (>32). Only 33/54 (61%) observations
at or greater than 3 months had a positive response.
Conclusions: Our study suggests that an absence of a history of syphilis and an initial high RPR
titer are predictive of a positive response following appropriate treatment. Given the low percentage
ofobservations with a positive response at 3 months, we speculate that we may be undertreating our
pregnant patients with syphilis infection. Infect. Dis. Obstet. Gynecol. 5:23-28, 1997.
(C) 1997 Wiley-Liss, Inc.
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yphilis has sustained a recent resurgence in the
United States. The incidence of syphilis in 1990
is the highest since 1950.1 Additionally, the inci-
dence of syphilis in pregnancy and of congenital
syphilis has risen in parallel fashion. According to
the Centers for Disease Control (CDC), 35% of
neonatal infections are related to treatment failures
which can occur as a result of reinfection, severe
infection, or treatment late in pregnancy, z,3 Cur-
rently, the recommended treatment for syphilis in
pregnancy is based on guidelines set by the CDC
which are based on experience with nonpregnant
patients. Several studies have addressed the inef-
fectiveness of treatment of syphilis during preg-
nancy.
4-6
In 1993, Nathan et al.6 demonstrated that a
single dose of 2.4 million units of benzathine peni-
cillin G given at term results in a wide range of
penicillin levels in various maternal-fetal compart-
ments. They speculated that altered pharmacoki-
netics may affect the efficacy of this drug for pre-
vention of congenital syphilis in the near term ges-
*Correspondence to: Dr. Henry L. Galan, Department of OB/GYN, University of Colorado Health Science Center, Cam-
pus Box B-198, 4200 E. 9th Avenue, Denver, CO 80262. E-mail: galanh@jove.uchsc.edu
Clinical Symposium
Received 22 August 1996
Accepted 5 May 1997SYPHILIS SEROLOGY IN PREGNANCY GALANET AL.
TABLE I. CDC guidelines for treatment of syphilis
Stage of syphilis Treatment
Early syphilis (I o, 2o, latent syphilis of <1 year duration)
Latent syphilis of unknown duration or >2 years duration,
cardiovascular, or late benign syphilis
Neurosyphilis
Benzathine penicillin G 2.4 MU IM x
Benzathine penicillin G 2.4 MU IM weekly x 3 weeks
Aqueous crystalline penicillin G 2-4 MU IV every 4 h for 10
days, or aqueous procaine penicillin G 2.4 MU IM plus
probenecid 500 mg PO 4 times daily; both daily for 10 days to
be followed by benzathine penicillin G 2.4 MU IM weekly for 3
weeks
tation. Pregnancy-related physiologic changes such
as expanded blood volume and volume of distri-
bution is one of several variables that could poten-
tially affect nonspecific serologic markers of syphi-
lis such as the venereal disease research labora-
tory (VDRL) or rapid plasma reagin (RPR) tests.
Adequate treatment of syphilis is conventionally
documented in nonpregnant individualg by a 4-
fold decrease in VDRL or RPR titers over a 3-
month period of time.7-11 While the expected de-
crease in RPR is based on studies of nonpreg-
nant patients, this expected decrease is also used in
the pregnant patient to assess adequacy of treat-
ment or the need for retreatment. No study has
specifically evaluated the pattern of post-syphilis
treatment nontreponemal antibody titers in preg-
nancy. The purpose of this study is to assess the
effect of several maternal variables on the serologic
response in patients treated for syphilis during
pregnancy.
SUBJECTS AND METHODS
This is a retrospective study of pregnant patients
who were evaluated for syphilis over a 5-year pe-
riod (1988-1993) at the University of Texas Health
Science Center at Houston and Hermann Hospital.
Administrative approval was obtained from the
Committee for Protection of Human Subjects for a
chart review. Patient inclusion criteria were 1) se-
rologic documentation of syphilis infection during
the index pregnancy, 2) complete treatment given
during the index pregnancy, and 3) completion of
treatment using CDC guidelines. Exclusion crite-
ria were 1) a history of syphilis completely treated
prior to the index pregnancy, 2) a treatment regi-
men outside of the CDC guidelines, 3) lack of any
follow-up titers, 4) completion of treatment in the
postpartum period, and 5) human immunodeficien-
cy virus (HIV) positivity.
The diagnosis of syphilis was based on serologic
testing using the RPR and confirmed with the mi-
crohemagglutination test for T. pallidum (MHA-
TP). Either a 4-fold increase in titer or a titer of
-> 1" 16 in a patient with a previous history of syphi-
lis treatment would be considered inadequate
treatment or reinfection. Identification of spiro-
chetes from primary or secondary lesions by dark-
field microscopy was also considered diagnostic.
Treatment of syphilis was in accordance with CDC
guidelines which are listed in Table 1. RPR titers
were used to evaluate the response to treatment. At
our institution, RPR titers are performed monthly
for the remainder of the pregnancy following
completion of syphilis treatment. Staging was
documented according to the stage at the time of
treatment as recorded in the chart. Treatment was
documented either by contact with the sexually
transmitted disease (STD) Hotline or based on
what was documented in the chart. The patient’s
partner is typically treated and is encouraged to
follow-up at the local health department, however,
partner compliance was not assessed in this study.
Maternal variables assessed included 1) history
of syphilis either untreated or incompletely treated
prior to the index pregnancy (completely treated
pregestational syphilis patients were excluded), 2)
stage of disease as assigned at the time of treat-
ment, 3) gestational age at the time of treatment, 4)
pretreatment RPR titers, 5) post-treatment RPR
titers, and 6) race. These data were presented in
dichotomous fashion for purposes of analysis.
Therefore, the maternal variables for each patient
were categorized as follows: 1) history vs. no history
of pregestational syphilis, 2) unknown vs. known
duration of syphilis, 3) early (<20 weeks gestation)
vs. late gestational disease, 4) high (> 1"32)vs. low
initial titer, 5) post-treatment titer at month (___2
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weeks) vs. after month, 6) post-treatment titer at
2 months (+2 weeks) vs. after 2 months, 7) post-
treatment titer at 3 months (_+2 weeks) vs. after 3
months, and 8) black vs. non-black race. High or
low pretreatment titer levels were divided into > 1:
32 or <1:32, respectively. This number was chosen
because 1:32 was the median titer of all titers re-
corded.
Treatment response was assessed by comparing
each patient’s post-treatment titer to her pretreat-
ment titer. Each comparison was considered an
"observation." For example, if a patient had only a
pretreatment titer available, this would be "0" ob-
servations, and this patient would be excluded. If a
patient had a pretreatment titer and one post-
treatment titer, this would be considered one ob-
servation. Two post-treatment titers would be con-
sidered two observations, and in this case the com-
parison of the pretreatment titer to the first post-
treatment titer would be one observation, and the
pretreatment titer to the second post-treatment ti-
ter would be the second observation. Observations
were not made between post-treatment titers, but
only between pretreatment and post-treatment ti-
ters. Each observation was categorized as either a
positive response (->4-fold titer decline) or nega-
tive response (<4-fold titer decline) to treatment.
In our laboratory, RPR titers are reported as tube
dilutions. A 2-tube dilution is equivalent to a 4-fold
decline in titers (i.e., 1:16 to 1:4 response is a 2-
tube dilution decline or a 4-fold decline).
Statistical Analysis
Statistical analysis was performed with the True
Epistat statistical package (Epistat Services, Rich-
ardson, TX). Maternal variables and their impact
on positive titer responses were analyzed using
Fisher’s exact or chi-square tests and P < 0.05 was
considered significant. For assessing the effect of
race on positive titer response, the contingency
table was subdivided and analyzed with Fisher’s
exact test. Because the contingency table for race
was subdivided, the Bonferroni inequality was ap-
plied and the P value adjusted from <0.05 to
<0.02.
RESULTS
A computer-generated report of pregnant patients
with a code of syphilis between January 1, 1988,
TABLE 2. Demographic data of study population
Total study patients 49
Maternal age, years (range) 22.8 (15-40)
EGA at initial prenatal visit, weeks (range) 24.9 (9-40)
Parity
Nulliparous II (22%)
Multiparous 38 (78%)
Race
Black 44 (90%)
Hispanic 4 (8%)
White 1(2%)
Stages of syphilis
Primary 3
Secondary 2
Early latent 24
Unknown duration 20
and December 31, 1993, revealed a total of 290
patients. Of these 290 patients, 95 were followed in
the University of Texas Women’s Clinic and had
complete records. Of these 95, 41 had a history of
appropriately treated syphilis prior to the index
pregnancy, and were therefore excluded. An addi-
tional 5 patients were excluded because only the
pretreatment titer was available. Of the 95 patients,
a total of 49 met the inclusion criteria for the study.
These 49 patients provided a total of 98 "observa-
tions." Table 2 shows the demographic data of the
study population. In addition, 36 were without a
history of previous syphilis infection. Two patients
had a negative RPR screen on their initial prenatal
visit with a subsequent positive RPR at 28 weeks.
The majority of patients (>95%) had an initial RPR
screen that was positive. The majority of patients
had early latent syphilis (24) and syphilis of un-
known duration (20). Two of the 49 patients were
HIV positive and were excluded because of reports
that RPR titers may fall slower in patients who
have HIV infection. CDC treatment guidelines
were followed and there were no penicillin allergic
patients.
Table 3 shows the effect of maternal variables
on positive responses. Two of the 8 variables sig-
nificantly impacted positive titer responses. Those
patients with a pregestational history of syphilis
(13/32) were significantly less likely (P < 0.05) to
have a positive response than those without a pre-
vious history of syphilis (41/66). Those patients
with a high RPR titer (36/51) were significantly
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TABLE 3. Maternal variables having a positive
response (->4-fold decrease in titer) with
corresponding P values
Maternal variables Positive treatment responses
Prior history
Yes 13/32 (40%)*
No 41/66(62%)*
Early disease
Yes 21/49 (43%)
No 17/49 (35%)
Initial RPR
High (->1:32) 36/51 (70%)*
Low (<1:32) 18/47 (30%)*
Duration
Known 33/64 (5 I%)
Unknown 21/34 (62%)
Black race
Yes 52/88 (59%)
No 4/10 (40%)
Observations
At month 10/23 (43%)
vs.>l month 44/75 (59%)
At 2 months 9/21 (43%)
vs.>2 months 34/54 (63%)
At 3 months 1/20 (55%)
vs.>3 months 22/34 (65%)
*P < 0.05.
more likely (P < 0.005) to have a positive response
than those with low titers (18/47). The other 6 vari-
ables were found not to be significant factors for a
positive response. The number of observations
showing a positive treatment response when the
post-treatment titers were obtained at month (1
month ___
2 weeks) was not significantly different
when compared to those in which the post-
treatment titer was obtained at >1 month (i.e., 2
months, 3 months, etc.). The same nonsignificant
findings were encountered for the observations of
post-treatment titers at 2 months (2 months + 2
weeks) when compared to those in which the post-
treatment titers were obtained at >2 months (i.e., 3
months, 4 months, etc.). The same findings were
also noted for the observations of post-treatment
titers at 3 months (3 months + 2 weeks) when com-
pared to those in which the post-treatment titers
were obtained at >3 months.
DISCUSSION
A number of studies suggest that certain infections
have a higher incidence in pregnancy and that they
may be more difficult to treat. These include po-
liomyelitis, hepatitis A and B, and malaria. 1e-is
Syphilis may also be considered in that group. The
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reason for the difficulty of syphilis treatment in
pregnancy remains to be elucidated, but may be
due to an altered immune response (acceptance of
a partially allogenic fetus), reinfection, severity of
infection, or that the method of assessment of cure
is altered by physiologic volume changes in preg-
nancy. While the treatment of syphilis in the non-
pregnant patient is very effective, treatment in the
pregnant patient may have a high failure rate ac-
counting for as much as 35% of neonatal infec-
tions, e,3 Our findings show that only 55% of obser-
vations where the post-treatment titer was ob-
tained at 3 months demonstrated a positive
response (4-fold titer decline), and only 65% of ob-
servations in which the post-treatment titer was
obtained at >3 months demonstrated a positive re-
sponse. This suggests inadequate treatment which
may contribute to the relatively high failure rate
seen in pregnancy. As described by Nathan et al.,6
the causes are likely to be multifactorial and may
include advanced fetal disease, the Jarisch-
Herxheimer reaction, altered penicillin pharmaco-
kinetics in pregnancy, and altered maternal and fe-
tal immune responses.
Nathan ct al.6 speculated that physiological
changes occurring in pregnancy may result in alter-
ations of penicillin pharmacokinetics leading to re-
duced penicillin levels. Changes such as expanded
blood volume and volume of distribution could also
potentially affect the way that nonspecific serologic
markers of syphilis such as the VDRL or RPR re-
spond in pregnancy. This is a critical issue consid-
ering that the assessment of successful treatment or
the need for retreatment is based on convalescence
ofVDRL or RPR titers. If the titer levels and pat-
terns differ from the nonpregnant state, then per-
haps the normally expected 4-fold decrease over a
3-month period of time that is seen in the nonpreg-
nant state should be reconsidered for the pregnant
female. Depending on the rapidity or delay of titer
decline, we may be over- or undertreating our pa-
tients. Our study suggests that of the maternal vari-
ables studied, an absence of a pregestational his-
tory of syphilis and a high initial titer are significant
factors for predicting a positive response. Our find-
ing that a pregestational history of syphilis alters
the rate of RPR titer decline in the subsequent
pregnancy in comparison with those patients with-
out a history of syphilis may be due to previous
inadequate treatment or persistent infection whichSYPHILIS SEROLOGY IN PREGNANCY GALANET AL.
over time had become more advanced. This is con-
sistent with a recent abstract by McFerlin et al.
(IDSOG, 1995)which demonstrated that women
who have had syphilis in a previous pregnancy are
at high risk of delivering an infant with congenital
syphilis in the subsequent pregnancy.
Ideally, a study assessing the response of syphi-
lotherapy in pregnancy should be performed in a
prospective controlled fashion using matched, non-
pregnant patients as controls. Our study was lim-
ited by the small number of patients eligible for the
study which required us to establish "observa-
tions" to assess positive treatment responses to
therapy. Positive treatment responses should ide-
ally be assessed within each individual patient in-
stead of as "observations" which combine the data
from all patients. There is sufficient variation in
laboratory serologic work such that a. failure to
reach a 4-fold decrease after 3 months may not
necessarily indicate inadequate treatment since the
next monthly titer may subsequently reflect an ap-
propriate decline in titer. A second limitation is
from an analytical viewpoint where the maternal
variables should be treated as independent vari-
ables, thereby implying the need for a multivariate
analysis. A third potential retrospective bias is that
our data were obtained by chart review and we
were dependent on accurate documentation of
staging and treatment. This could result in misclas-
sificatio of patients, e.g., including patients into
the study with low titers who were previously
treated which would bias "low titer" patients as
nonresponders. However, the inclusion criteria for
"low titer" patients were stringent and required
that patients meet the CDC recommendations
for infection of a 4-fold rise in RPR titer. A fourth
limitation is the lack of available neonatal follow-
up which is needed to substantiate specula-
tions regarding adequacy of maternal and fetal
therapy.
Another finding in our study which could poten-
tially have a clinical impact was the lack of a sig-
nificant difference in positive responses when ob-
servations in which post-treatment titers at
month were compared to observations in which
post-treatment titers were obtained at >1 month.
This suggests that we may be able to detect early
on whether a patient is going to respond appropri-
ately to treatment. However, this interesting find-
ing should be tempered by the small number of
patients in this study. While our study has some
limitations, it calls attention to the need for further
studies regarding the proper interpretation of sero-
logic titers in pregnancy which may be different
from the nonpregnant patient. Assuming that titers
fall the same in the pregnant and nonpregnant state
and that the CDC guidelines for assessing appro-
priate titer decline to therapy are applicable in
pregnancy, our data suggest that we are undertreat-
ing our pregnant patients with syphilis infections or
that patients are becoming reinfected during preg-
nancy either by an untreated partner or inadequate
fetal treatment. This is consistent with other stud-
ies in the literature. While the endpoints of several
studies addressing the adequacy of current CDC
treatment guidelines have included congenital
syphilis and/or maternal-fetal penicillin levels, our
study is the first to address the endpoint with re-
spect to maternal serology and can serve as a pilot
study on which future studies may be based. In
addition, further studies are needed to compare the
serologic responses between the pregnant and non-
pregnant patient.
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